[go: up one dir, main page]

CL2014001263A1 - Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases. - Google Patents

Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.

Info

Publication number
CL2014001263A1
CL2014001263A1 CL2014001263A CL2014001263A CL2014001263A1 CL 2014001263 A1 CL2014001263 A1 CL 2014001263A1 CL 2014001263 A CL2014001263 A CL 2014001263A CL 2014001263 A CL2014001263 A CL 2014001263A CL 2014001263 A1 CL2014001263 A1 CL 2014001263A1
Authority
CL
Chile
Prior art keywords
binding molecule
bcma
cell
cell disorders
encodes
Prior art date
Application number
CL2014001263A
Other languages
Spanish (es)
Inventor
Eric Borges
Paul Adam
Peter Kufer
Tobias Raum
Patrick Hoffmann
Roman Kischel
Ralf Lutterbuese
Doris Rau
Barbara Hebeis
Susanne Hipp
Original Assignee
Boehringer Ingelheim Int
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52002373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014001263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Amgen Res Munich Gmbh filed Critical Boehringer Ingelheim Int
Publication of CL2014001263A1 publication Critical patent/CL2014001263A1/en

Links

CL2014001263A 2011-11-15 2014-05-14 Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases. CL2014001263A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161560178P 2011-11-15 2011-11-15
US201161560144P 2011-11-15 2011-11-15
US201161560162P 2011-11-15 2011-11-15
US201161650149P 2011-11-15 2011-11-15
US201161560183P 2011-11-15 2011-11-15
US201261651486P 2012-05-24 2012-05-24
US201261651474P 2012-05-24 2012-05-24

Publications (1)

Publication Number Publication Date
CL2014001263A1 true CL2014001263A1 (en) 2014-10-10

Family

ID=52002373

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014001263A CL2014001263A1 (en) 2011-11-15 2014-05-14 Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.

Country Status (1)

Country Link
CL (1) CL2014001263A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11434302B2 (en) 2016-02-03 2022-09-06 Amgen Research (Munich) Gmbh Bispecific T cell engaging antibody constructs
US11447567B2 (en) 2015-07-31 2022-09-20 Amgen Research (Munich) Gmbh Antibody constructs for FLT3 and CD3
US11884720B2 (en) 2015-07-31 2024-01-30 Amgen Research (Munich) Gmbh Antibody constructs for MSLN and CD3
US12428491B2 (en) 2016-02-03 2025-09-30 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447567B2 (en) 2015-07-31 2022-09-20 Amgen Research (Munich) Gmbh Antibody constructs for FLT3 and CD3
US11884720B2 (en) 2015-07-31 2024-01-30 Amgen Research (Munich) Gmbh Antibody constructs for MSLN and CD3
US11434302B2 (en) 2016-02-03 2022-09-06 Amgen Research (Munich) Gmbh Bispecific T cell engaging antibody constructs
US12428491B2 (en) 2016-02-03 2025-09-30 Amgen Research (Munich) Gmbh PSMA and CD3 bispecific T cell engaging antibody constructs

Similar Documents

Publication Publication Date Title
CL2014001254A1 (en) Bispecific binding molecule for bcma and cd3; nucleic acid sequence that encodes it; vector; cell; pharmaceutical composition comprising the binding molecule; use to treat diseases related to plasma cell disorders, b cell disorders correlated with bcma expression and autoimmune diseases.
CY1122399T1 (en) COMPETITIVE TNF RECEPTOR BINDING FACTORS
CL2015000256A1 (en) Heteroaromatic compounds, btk inhibitors, pharmaceutical composition that comprises them and use in diseases such as rheumatoid arthritis, lupus, among others.
AR090923A1 (en) ANTI-IL-23 ANTIBODIES
CL2013000338A1 (en) Binding protein that has the ability to bind interleukin 1beta and interleukin 17; crystallized binding protein conjugate; nucleic acid, vector, host cell; method to produce a binding protein; pharmaceutical composition comprising the binding protein.
HK1206780A1 (en) Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
IL241332A0 (en) Bispecific binding molecules for bcma and cd3, compositions comprising same and uses thereof
AR090903A1 (en) ANTI-PMEL ANTIBODIES AND IMMUNOCADES17
PH12014501108A1 (en) Anti-il-36r antibodies
PE20190229A1 (en) ANTI-FCRN ANTIBODIES
DK2963113T3 (en) PROCEDURE FOR ISOLATING SPECIFIC GENOMREGION USING MOLECULES BINDING SPECIFIC TO ENDOGENIC DNA SEQUENCE
CL2014000631A1 (en) Binding molecule that binds to cd134 (ox40); nucleic acid molecule that encodes it; vector; host cell; Preparation process; pharmaceutical composition that includes it; and its use to treat cancer.
BR112013029893A2 (en) cd3 binding molecule, cd3 binding antibody, cd3 binding antibody and pharmaceutical composition
IL230662A0 (en) Indazole-type substances, preparations containing these substances and their uses
EA201401077A1 (en) BISPECIFIC ANTIBODIES TO HUMAN TWEAK AND HUMAN IL17 AND THEIR APPLICATION
AR089528A1 (en) DUAL VARIABLE DOMAIN OF IMMUNOGLOBULINS AND THEIR USES
CL2014002072A1 (en) Cx3cr1 binding polypeptides; nucleic acid molecule that encodes it; pharmaceutical composition that contains it; method of elaboration of the peptide; uses of the peptide; kit containing the peptide.
NZ717399A (en) Antibodies against csf-1r
MX2016005956A (en) SPECIFIC ANTIBODIES FOR FCRN.
CL2014003167A1 (en) Binding molecule that specifically binds inteleukin 6 (il-6); pharmaceutical composition comprising it; nucleic acid; vector; host cell; and use to treat disease or disorder associated with il-6.
SI3200822T1 (en) Binding molecules, especially antibodies, binding to l1cam (cd171)
WO2015160928A3 (en) Isolated t cell receptors and methods of use therefor
CL2014002951A1 (en) (r) -nifuratel; pharmaceutical formulation that contains it; and process to manufacture (r) -nifuratel and (s) -nifuratel.
MX2022006304A (en) Compositions and methods for inhibiting the biological activity of soluble biomolecules.
EA201301090A1 (en) ANTI-AUDIO ANTICOAGULANTS